Navigation Links
Janssen Submits New Drug Application to U.S. FDA for Simeprevir (TMC435) for Combination Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C
Date:3/28/2013

pensated liver disease. Simeprevir is believed to work by blocking the protease enzyme that enables the hepatitis C virus to survive and replicate in host cells.

For additional information about simeprevir clinical studies, please visit www.clinicaltrials.gov.

About Hepatitis C
Hepatitis C, a blood-borne infectious disease of the liver and a leading cause of chronic liver disease, is the focus of a rapidly evolving treatment landscape. Approximately 150 million people are infected with hepatitis C worldwide - including approximately 3.2 million people in the United States - and 350,000 people per year die from the disease globally. When left untreated, HCV can cause significant damage to the liver including cirrhosis. Additionally, hepatitis C may increase the risk of developing complications from cirrhosis, which can include liver failure.

About Janssen Research & Development, LLC
Janssen Research & Development, LLC is headquartered in Raritan, N.J. and has affiliated facilities in Europe, the United States and Asia. Janssen Research & Development is leveraging a combination of internal and external innovation to discover and develop novel medicines and solutions in five distinct therapeutic areas: Neuroscience, Oncology, Immunology, Infectious Diseases and Vaccines, and Cardiovascular and Metabolism. For more information about Janssen Research & Development, LLC visit www.janssenrnd.com.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995.  The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events.  If underlying assumptions prove inacc
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Janssen Launches EXPLORER, Global Cardiovascular Research Program, Beginning with Five New Studies in Patients with Unmet Medical Needs
2. Janssen Pharmaceutica, NV, Funds New Global Mental Health Scholarships as Part of Its Healthy Minds Program
3. Janssen Neuroscientists and Colleagues Challenge Healthcare Industry to Create Integrated Approaches to Healthcare Innovation in Newly Published Article
4. Janssen Labs at San Diego Expands to Add Concept Lab and Open Collaboration Space to Accommodate Individual Entrepreneurs and Additional Life Science Start-Ups
5. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
6. Janssen Research & Development Announces Establishment of Global Cross-Pharmaceutical Clinical Trial Investigator Databank
7. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
8. Janssen and Johnson & Johnson to Provide Webcast Presentation of Immunology Pivotal Phase 3 Data Being Presented at the American College of Rheumatology Annual Meeting
9. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
10. West Announces Agreement with Janssen Biotech to Develop and Commercialize a New Self-injection Technology
11. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... -- Research and Markets has announced the ... by Reagent, by Application - Global Forecast to 2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Biopharmaceuticals are pharmaceutical products ... the most important and widely used techniques for biopharmaceutical ... the cell culture market in 2013. Growth in the ...
(Date:7/22/2014)... , July 22, 2014  Decision Resources Group finds that ... Canada will remain relatively stagnant at a value ... fact that percutaneous coronary intervention (PCI) volumes are growing faster ... markets, such as the United States ... largely driven by the increase in penetration of PCI procedures ...
(Date:7/22/2014)... , July 22, 2014 Legislation backed ... Access to Local Pharmacies Act of 2014") championing ... D would undermine the availability of lower cost ... $21 billion over the next 10 years, according ... by the Pharmaceutical Care Management Association (PCMA). ...
Breaking Medicine Technology:Global Cell Culture (Bioreactor, Incubator, Centrifuge) Market - Forecast to 2018 2Global Cell Culture (Bioreactor, Incubator, Centrifuge) Market - Forecast to 2018 3The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 2The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 3New Study: H.R. 4577 to Cost $21 Billion over 10 Years 2New Study: H.R. 4577 to Cost $21 Billion over 10 Years 3
(Date:7/22/2014)... of research at the University of Utah,s John A. ... Society of Eye Research (ISER) as the recipient of ... International Award in Retina Research., The award recognizes lifetime ... significant contribution to the understanding of vitreoretinal diseases or ... the ISER Biennial Meeting in San Francisco, where Marc ...
(Date:7/22/2014)... comes to heart disease, Dr. Ross Feldman says women are ... disease was a men,s-only disease, however, data has shown that ... heart disease and are less likely to be adequately diagnosed ... week in the British Journal of Clinical Pharmacology ... women and helps to identify which women are more prone ...
(Date:7/22/2014)... 22, 2014) -- The American Society of Hematology (ASH) ... H. Coulter Award for Lifetime Achievement in Hematology, to ... Island Jewish (LIJ) School of Medicine for his 50-year ... education and mentoring, and exceptional patient care. , ... Hematology is bestowed on an individual who has been ...
(Date:7/22/2014)... 2014 Legislation backed by the ... Local Pharmacies Act of 2014”) championing so-called “any ... undermine the availability of lower cost preferred pharmacy ... over the next 10 years, according to new ... Pharmaceutical Care Management Association (PCMA). , The drugstore ...
(Date:7/22/2014)... As reported on July 17, 2014 by ABC ... her favorite beauty products, “ Botox , that’s pretty much ... Botox has changed my life” by halving the amount ... her various, daily appearances. “Suddenly my eyelids are no ... , “I think that Kelly Ripa’s response to the question ...
Breaking Medicine News(10 mins):Health News:University of Utah researcher Robert Marc receives Paul Kayser International Award 2Health News:Gene variant identified as a heart disease risk factor for women 2Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 2Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 3Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 4Health News:PCMA: New Study Finds H.R. 4577 to Cost $21 Billion Over 10 Years 2Health News:Celebrity Botox: Kelly Ripa Confesses to Getting Botox Injections 2
... multispecialty medical group in Southern California, announced the opening of its ... Monrovia. , ... Torrance, CA (PRWEB) December 16, 2008 ... Southern California, announced the opening of its newest medical office ...
... portal that features the latest news, facts and nutritional updates about ... acai plant and the acai berry fruit to help the general ... ... Dallas, TX (PRWEB) December 16, 2008 -- The announcement ...
... Inc.(CTI),(Nasdaq and MTA: CTIC) announced today they have ... a 50/50 owned joint venture, RIT,Oncology LLC (LLC), ... United States. In connection with the closing, ... and will receive an,additional $7.5 million in early ...
... Dec. 15 Today, the U.S. Food,and Drug Administration ... along with diet to help lower triglycerides,and LDL cholesterol, ... TRILIPIX is the first and only fibrate to ... In certain patients, treatment guidelines,recommend the combination of a ...
... Calif.) -- A secondary analysis of a large, multicenter ... fruits, vegetables and fiber and somewhat lower in fat ... of recurrence in a subgroup of early-stage breast cancer ... by approximately 31 percent. These patients typically have higher ...
... say , , MONDAY, Dec. 15 (HealthDay News) -- Men ... spread beyond the wall of the prostate gland -- ... risk of dying in half, a new study has ... much longer, the Swedish research team concluded. In fact, ...
Cached Medicine News:Health News:HealthCare Partners Opens a New Medical Office in Monrovia, CA 2Health News:AcaiBerryMD.com Explains the Real Facts About the Acai Berry Fruit 2Health News:AcaiBerryMD.com Explains the Real Facts About the Acai Berry Fruit 3Health News:Cell Therapeutics and Spectrum Pharmaceuticals Close Transaction Forming Joint Venture to Market Zevalin in the US 2Health News:Cell Therapeutics and Spectrum Pharmaceuticals Close Transaction Forming Joint Venture to Market Zevalin in the US 3Health News:Cell Therapeutics and Spectrum Pharmaceuticals Close Transaction Forming Joint Venture to Market Zevalin in the US 4Health News:Cell Therapeutics and Spectrum Pharmaceuticals Close Transaction Forming Joint Venture to Market Zevalin in the US 5Health News:(Multimedia Version): Abbott Receives FDA Approval for TRILIPIX(TM) (fenofibric acid), First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management 2Health News:(Multimedia Version): Abbott Receives FDA Approval for TRILIPIX(TM) (fenofibric acid), First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management 3Health News:(Multimedia Version): Abbott Receives FDA Approval for TRILIPIX(TM) (fenofibric acid), First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management 4Health News:Diet may cut risk of breast cancer recurrence in women without hot flashes 2Health News:Diet may cut risk of breast cancer recurrence in women without hot flashes 3Health News:Radiation Plus Hormone Therapy Cuts Prostate Cancer Deaths 2Health News:Radiation Plus Hormone Therapy Cuts Prostate Cancer Deaths 3
... The AlphaPette Pipettor is the #1 ... Offers accuracy, comfort, and reliability. Continuously ... volume readout sub-micrometer. Easy interchangeable ejector ... tiny hands. Adjustable rapid pipet tip ...
... The Finnpipette Digital offers improved ergonomics ... rounded handle, modified grippy finger rest ... operator comfort and efficiency. Finnpipette Digitals ... power-boosted gearing mechanism (pat. pend.) and ...
... is the #1 Pipettor for sub-microliter ... and reliability. Continuously adjustable. Features lPLUS, ... Easy interchangeable ejector buttons to fit ... rapid pipet tip ejector with three ...
... Recommended for aqueous samples of moderate viscosity and density. Proven ergonomic design ... Volume Range(ul) ... 0.8~1.5 Imprecision(%) ... (ul) ...
Medicine Products: